Pelthos reports Q3 '26 financial results; net product revenue up 114%
Pelthos Therapeutics announced Q3 2026 financial results showing $15.2 million in net product revenue for Zelsuvmi, driven by significant growth and a strategic merger with Castle Creek. The company expects to expand growth with upcoming product launches in 2027.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed